Skip to content

Pacira BioSciences, Inc. PCRX Net Investment in Lease

Net Investment in Lease at other companies

Avanos Medical logo
Avanos MedicalAVNS
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
AtriCure logo
AtriCureATRC

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s net investment in lease?
Pacira BioSciences, Inc. (PCRX) reported net investment in lease of $39.41M in Q1 2026.
How has Pacira BioSciences, Inc.'s net investment in lease changed year-over-year?
Pacira BioSciences, Inc.'s net investment in lease decreased by 19.1% year-over-year, from $48.73M to $39.41M.
What is the long-term trend for Pacira BioSciences, Inc.'s net investment in lease?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s net investment in lease has grown at a -10.9% compound annual growth rate (CAGR), from $74.49M to $41.78M.